Luke Evnin Sells 79,086 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 79,086 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $0.63, for a total transaction of $49,824.18. Following the transaction, the director directly owned 1,578,749 shares in the company, valued at approximately $994,611.87. This represents a 4.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.66, for a total transaction of $9,659.10.
• On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $4,733.40.
• On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total transaction of $34,533.36.
• On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total value of $42,627.62.
• On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total value of $121,148.64.
• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total value of $39,025.71.
• On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total value of $69,650.76.
• On Monday, April 27th, Luke Evnin sold 53,940 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.85, for a total value of $45,849.00.

Werewolf Therapeutics Stock Down 4.6%

Shares of HOWL traded down $0.03 during trading hours on Thursday, hitting $0.62. 616,751 shares of the company were exchanged, compared to its average volume of 410,169. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $2.38. The company has a market cap of $30.13 million, a price-to-earnings ratio of -0.46 and a beta of 0.41. The firm’s fifty day moving average is $0.81 and its 200 day moving average is $0.86.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. Analysts anticipate that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Wall Street Analyst Weigh In

HOWL has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen upgraded Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.75.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of hedge funds have recently bought and sold shares of HOWL. Regal Investment Advisors LLC boosted its position in Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after acquiring an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. boosted its position in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after acquiring an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Werewolf Therapeutics during the 2nd quarter valued at about $48,000. AQR Capital Management LLC bought a new stake in shares of Werewolf Therapeutics during the 1st quarter valued at about $79,000. Finally, Bridgeway Capital Management LLC grew its stake in Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares during the period. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.